Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells
- 11 September 2008
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 16 (1) , 111-118
Abstract
Gene therapy has proven to be of potential value for the correction of inherited hematopoietic disorders. However, the occurrence of severe side effects in some of the clinical trials has questioned the safety of this approach and has hampered the use of long terminal repeat-driven vectors for the treatment of a large number of patients. The development of self-inactivating (SIN) vectors with reduced genotoxicity provides an alternative to the currently used vectors. Our initial attempts to use SIN vectors for the correction of a myeloid disorder, chronic granulomatous disease, failed due to low vector titers and poor transgene expression. The optimization of the transgene cDNA (gp91phox) resulted in substantially increased titers and transgene expression. Most notably, transgene optimization significantly improved expression of a second cistron located downstream of gp91phox. Thus, optimization of the transgene sequence results in higher expression levels and increased therapeutic index allowing the use of low vector copy numbers per transduced cell and weaker internal promoters.Keywords
This publication has 44 references indexed in Scilit:
- An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activationBlood, 2008
- Retroviral integration and human gene therapyJournal of Clinical Investigation, 2007
- Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapyJournal of Clinical Investigation, 2007
- Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivoJournal of Clinical Investigation, 2007
- Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapyJournal of Clinical Investigation, 2007
- Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cellsDNA Repair, 2007
- Gene therapy for severe combined immunodeficiency: are we there yet?Journal of Clinical Investigation, 2007
- Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicityBlood, 2006
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001